Signify Welcomes Dr. Carrie Kuehn, RAC-US to Its Regulatory Advisory Board

Signify is pleased to announce the appointment of Dr. Carrie Kuehn, MA, MPH, DLP, RAC-US to its Regulatory Advisory Board. With over 25 years of distinguished experience in clinical and regulatory affairs within the medical device industry, Dr. Kuehn brings exceptional expertise to enhance Signify's engagement with the regulatory affairs community.

Dr. Kuehn's extensive background in navigating the complexities of medical device clinical research, product development, and market authorizations provides a valuable perspective on the challenges manufacturers face in today's regulatory landscape. Her appointment underscores Signify's commitment to bridging compliance requirements with innovative solutions.

"Regulatory compliance is fundamental to ensuring life-saving innovations reach the market safely and efficiently," said Martín Ramírez, CEO at Signify. "Dr. Kuehn's insights will be instrumental as we continue to expand our AI-powered compliance solutions designed to help manufacturers streamline processes, mitigate risk, and maintain compliance with evolving regulations."

At Signify, we’re committed to empowering consumer goods manufacturers, including medical device makers, with AI agents to streamline product compliance. Dr. Kuehn’s leadership and experience will help us build the best AI products that thousands of regulatory, quality, and compliance practitioners will trust to bring the best and safest products to market.

Advancing Regulatory Excellence

As regulatory requirements evolve and compliance frameworks become increasingly complex, Signify remains committed to providing industry-leading solutions guided by premier expertise. Dr. Kuehn's appointment to our Regulatory Advisory Board significantly enhances our capabilities in navigating these challenges.

Signify welcomes Dr. Kuehn and looks forward to her contributions to advancing our mission of regulatory excellence.